CD276 Recombinant Monoclonal Antibody

Code: CSB-RA733578MA1HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human, Cynomolgus

Application: ELISA, FC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

Q5ZPR3

Target Names

CD276

Alternative Names

4Ig B7 H3 antibody; 4Ig-B7-H3 antibody; AU016588 antibody; B7 H3 antibody; B7 homolog 3 antibody; B7-H3 antibody; B7H3 antibody; B7RP-2 antibody; CD_antigen=CD276 antibody; CD276 antibody; CD276 antigen antibody; CD276 molecule antibody; CD276_HUMAN antibody; Costimulatory molecule antibody; Flags: Precursor antibody; PSEC0249 antibody; UNQ309/PRO352 antibody

Species Reactivity

Human, Cynomolgus

Immunogen

Recombinant Human CD276 protein

Immunogen Species

Homo sapiens (Human)

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

hIgG1

Clone No.

5F9

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Tested Applications

ELISA, FC

Recommended Dilution

Application	Recommended Dilution
FC	1:50-1:200

Protocols

ELISA Protocol Flow Cytometry (FC) Protocol

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

The Binding Activity of Human CD276 with Anti-CD276 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized human CD276(CSB-MP5140MOV) at 2 μg/mL can bind Anti-CD276 recombinant antibody. The EC₅₀ is 4.299-5.373 ng/mL.
The Binding Activity of Human CD276 with Anti-CD276 recombinant antibody
Activity: Measured by its binding ability in a functional ELISA. Immobilized human CD276(CSB-MP733578HU(F2)) at 2 μg/mL can bind Anti-CD276 recombinant antibody. The EC₅₀ is 47.12-54.16 ng/mL.
Overlay Peak curve showing MCF7 cells stained with CSB-RA733578MA1HUMA1HU (red line) at 1:100. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated Goat Anti-human IgG(H+L) at 1:200 dilution for 35min at 4℃.Control antibody (green line) was human IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

CD276, also known as B7-H3, is an immune checkpoint molecule that has emerged as a compelling target in cancer immunology and immunotherapy research. As a member of the B7 family of co-stimulatory proteins, CD276 plays complex roles in modulating T cell responses and is frequently overexpressed across multiple tumor types while showing limited expression in normal tissues. This expression pattern makes it an attractive candidate for both diagnostic studies and therapeutic targeting strategies.

This recombinant monoclonal antibody, clone 5F9, offers researchers the consistency and reliability that comes with sequence-defined production. Unlike traditional hybridoma-derived antibodies, recombinant technology ensures lot-to-lot reproducibility, allowing you to maintain experimental continuity across long-term studies without concerns about antibody drift or batch variation.

Validation data demonstrates robust binding activity in functional ELISA assays, with EC50 values in the low nanogram per milliliter range when tested against immobilized human CD276 protein. Flow cytometry analysis using MCF7 cells confirms the antibody's ability to detect endogenous CD276 expression on human breast cancer cells, showing clear positive signal separation from isotype control. The antibody exhibits cross-species reactivity with both human and cynomolgus samples, supporting translational research workflows that bridge preclinical primate studies with human applications.

Supplied as a purified human IgG1 format in a glycerol-based buffer system, this antibody is well-suited for researchers investigating immune checkpoint biology, tumor microenvironment characterization, and cancer immunotherapy mechanisms. Its validated performance in ELISA applications at dilutions ranging from 1:5000 to 1:50000 provides flexibility for assay optimization across diverse experimental conditions.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

<p>Earlier studies found that B7H3 (also known as B7H3) promotes the activation of T cells. Chapoval et al. confirmed that in the presence of anti-CD3 antibodies, B7H3 can promote the proliferation of CD4 and CD8+ T cells and selectively promote the secretion of IFN-γ. And B7H3 transfection into tumor cells can enhance the killing ability of CTL. Further research found that only TLT-2 transgenic cells could bind to mouse B7H3 with high affinity, and TLT-2 was determined to be the receptor molecule of B7H3. Moreover, Hashiguchi et al. confirmed that the B7H3-TLT-2 pathway enhanced T cell activation. However, Leitner et al. did not find the specific binding of B7H3 to TLT-2 by flow cytometry, therefore, the exact receptor molecule of B7H3 is still unclear.<br />On the other hand, studies have found that B7H3 can also suppress T-cell immune responses. Some studies have shown that B7H3 can inhibit human and mouse T cells by activating or inhibiting NFTA (nuclear factor for activated T cells), NF-KB (nuclear factor kB) and AP-1 (activator protein-1) pathways. activation. In addition, results have demonstrated that B7H3 may inhibit T cell immune responses by inhibiting the activity of Thl. The study of Leiner et al. also found that B7H3 can down-regulate the secretion of IL-2 in T cells to inhibit the activity of T cells.</p>

Gene References into Functions

High B7-H3 expression is associated with phyllodes tumors. PMID:30486739
characterization of the expression pattern and biological function of B7-H3 in brain gliomas; B7-H3 expression is regulated by multiple mechanisms and is potentially involved in the T-cell receptor signaling pathway; higher B7-H3 expression indicates a worse prognosis for glioma patients PMID:30027617
High expression level of B7H3 in muscleinvasive bladder cancer (MIBC) tissues is associated with a poor clinico-pathological status and poor prognosis, and promotes the development of MIBC in vitro and in vivo. PMID:30132557
Tumor B7-H3 expression was significantly higher in immunocompetent vs. immunosuppressed patients, largely driven by very low expression in HIV+ patients. PMID:29484464
Colorectal cancer (CRC) patients expressing both high B7-H3 and high B3GALT4 contributed to a significant decrease in overall survival. The expression of B3GALT4 in CRC is positively correlated with B7-H3 expression in vitro. B7-H3/B3GLAT4 may be used as dual prognostic biomarkers for CRC. PMID:30131660
this study shows reduced sB7-H3 expression in the peripheral blood of systemic lupus erythematosus patients PMID:29423417
High B7-H3 expression is associated with cervical cancer invasiveness. PMID:28627681
IDH1 and B7H3 cannot be used as independent prognostic factors, co-expression of IDH1 and B7H3 significantly correlated with the prognosis of CRC patients and may serve as a combined predictive marker. Thus, the correlation between IDH1 and B7H3 has been proven in vivo and in vitro. PMID:29871819
Our findings revealed that B7-H3 affect ovarian cancer progression through the Jak2/Stat3 pathway, indicating that B7-H3 has the potential to be a useful prognostic marker. PMID:28765941
metastatic melanoma cells with knockdown expression of B7-H3 showed modest decrease in proliferation and glycolytic capacity. PMID:28513992
results suggest that B7-H3 may be a valuable biomarker in determining tumor progression and prognosis of intrahepatic cholangiocarcinoma PMID:29696716
these results demonstrate that sB7-H3 promotes invasion and metastasis through the TLR4/NF-kappaB pathway in pancreatic carcinoma PMID:27273624
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function PMID:28685773
Higher B7-H3 expression correlates with Gleason grade, prostate cancer stage and poor oncologic outcomes in prostatectomy cohorts. B7-H3 expression appears to be related to androgen signaling as well as the immune reactome. PMID:27801901
Review/Meta-analysis: High B7-H3 expression was a significant indicator of lymph node metastasis and advanced TNM stage in non-small cell lung cancer. PMID:27835582
B7-H3 promotes epithelial mesenchymal transformation in colorectal cancer cells by activating the PI3K-Akt pathway and upregulating the expression of Smad1. PMID:27145365
Plasma B7-H3 levels were decreased significantly in children subjected to pediatric general and cardiac surgery, which is closely associated with the severity of surgical stress. The negative correlation of plasma B7-H3 levels at day 1 and day 3 after surgery with surgical stress scoring implicates that the plasma B7-H3 level might be a useful biomarker for monitoring stress intensity during pediatric surgery. PMID:27459969
B7-H3 promotes the oxaliplatin resistance in colorectal cancer cells upregulating the expression of XRCC1 via PI3K-AKT pathway. PMID:28676400
Children with Mycoplasma pneumoniae pneumonia had significantly higher levels of sB7-H3 and IL-36 compared to control subjects. PMID:27188891
CD276 is broadly expressed by tumor cells and tumor vasculature but Is dispensable for tumor growth. PMID:28399408
B7-H3 hijacks SREBP-1/FASN signaling mediating abnormal lipid metabolism in lung cancer PMID:27939887
We found that B7-H3 promoted the Warburg effect, evidenced by increased glucose uptake and lactate production in B7-H3-expressing cells. B7-H3 also increased the protein levels of HIF1alpha and its downstream targets, LDHA and PDK1, key enzymes in the glycolytic pathway PMID:27197253
Upregulated sB7-H3 expression in MPEs is correlated with TNM stage of NSCLC and may serve as a potential biomarker for NSCLC-derived MPEs PMID:27071700
High expression of B7-H3 is associated with Colorectal cancer. PMID:26787540
Elevated B7-H3 expression is significantly associated with poor survival in cancer patients. (Meta-analysis) PMID:27626927
The results provide novel insights into the function of B7-H3 in cancer, and suggest that targeting of B7-H3 may be a novel alternative to improve current anticancer therapies. PMID:26771843
Suggesting that B7-H3 and Tregs may act cooperatively in tumor immune evasion, leading to poor outcomes for NSCLC patients. PMID:26823710
B7-H3 is one of the most strongly expressed B7-family molecules in AML and merits further investigation. PMID:26376842
findings demonstrate that activation-induced B7-H3 expression on synovial monocytes has the potential to inhibit Th1-mediated immune responses and immunomodulatory roles affecting RA pathogenesis. PMID:26702052
B7H3 promotes cell migration and invasion through the Jak2/Stat3/MMP9 signaling pathway in colorectal cancer PMID:26151358
B7-H1 and B7-H3 are independent predictors of poorer survival in patients with non-small cell lung cancer. PMID:25609202
B7-H3 may play an important role in asthma exacerbation and was a useful clinical biomarker to evaluate asthma exacerbation. PMID:26108069
found that the N-glycans of B7-H3 from Ca9-22 oral cancer cells contain the terminal alpha-galactose and are more diverse with higher fucosylation and better interaction with DC-SIGN and Langerin on immune cells than that from normal cells PMID:26438868
Study shows that B7-H3 promotes mantle cell lymphoma progression and its knockdown significantly enhances the chemosensitivity. PMID:25872657
These results demonstrated that B7-H3 expression in acute leukemia predicts an unfavorable outcome. PMID:25130683
Our results indicate that B7-H3 expression in cervical invasive squamous cell carcinoma may play an important role in overcoming CD8(+) T-cell immunoregulation to acquire aggressive growth. PMID:25675190
Data shows that B7-H3 is aberrantly expressed in gastric cancer. In addition to modulating tumor immunity, B7-H3 may have a novel role in regulating SGC-7901 cell metastasis. PMID:25120098
Overexpression of B7-H3 in CD14+ monocytes is associated with renal cell carcinoma progression.B7-H3 might play an important role in angiogenesis of renal cell carcinoma mediated by CD14(+) monocytes. PMID:25416051
Data show that immunoglobulin-like transcript 4 (ILT4) increases the expression of the co-inhibitory molecule B7-H3 through PI3K/AKT/mTOR signalling. PMID:26149216
IL-2/IL-2R and B7-H3 pathways may be involved in the progression of clear cell renal cell carcinoma PMID:25089268
The overexpression of B7-H3 induces resistance to apoptosis in colorectal cancer cell lines by upregulating the Jak2-STAT3 signaling pathway. PMID:25684945
B7-H3 was significantly up-regulated on monocytes in rheumatoid arthritis patients, while soluble B7-H3 in serum was decreased. A polymorphism variant, B7-H3-T-A-C-T, was shown to be associated with the incidence of RA and the decreased release of sB7-H3. PMID:25931383
B7-H3-mediated STAT3 signaling pathway is an important mechanism for inducing M2-type polarization of tumor associated macrophages. PMID:25370943
The study confirms the overexpression of B7-H3 in colorectal cancer and shows the main localization of the protein in cytoplasm and cell membrane. PMID:25139714
High level of serum B7-H3 in patients with Hepatocellular Carcinoma is caused by the increased expression of a newly discovered spliced soluble B7-H3 isoform in carcinoma and peritumor tissues. PMID:24194851
Data indicate that six sites of co-stimulatory molecule B7-H3 gene have single nucleotide polymorphisms variations and five sites are related to the pathogenesis of rheumatoid arthritis (RA). PMID:25200161
Study shows that CD276 can be used to discriminate ECs from malignant tissue from ECs from normal tissue. In addition, CD276(+) CEC do occur in higher frequencies in patients with advanced cancer. PMID:24892449
Data indicate that the expression of membrane B7-H3 (mB7-H3) in peri-tumor normal tissues was higher than that in tumor tissues, and it can serve as an assistant diagnostic marker for hepatitis B virus-associated hepatocellular carcinoma (HBV-HCC). PMID:25001942
B7H3 and ATP1B3 are overexpressed in tumor endothelial cells, favoring an angiogenic phenotype. PMID:24236063
Thus, B7-H3 may have a critical role in primary hepatocellular carcinoma and it may enhance tumor escape from the immune surveillance of CD8(+) T cells. PMID:24787022

Hide All

Subcellular Location

Membrane; Single-pass type I membrane protein.

Protein Families

Immunoglobulin superfamily, BTN/MOG family

Tissue Specificity

Ubiquitous but not detectable in peripheral blood lymphocytes or granulocytes. Weakly expressed in resting monocytes. Expressed in dendritic cells derived from monocytes. Expressed in epithelial cells of sinonasal tissue. Expressed in extravillous trophob

Database Links

HGNC: 19137

UNIGENE: Hs.744915

KEGG: hsa:80381

STRING: 9606.ENSP00000320084

OMIM: 605715

Promotions